
(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
JFK's granddaughter Tatiana Schlossberg reveals terminal cancer diagnosis - 2
Bother Control Administrations for 2024: Decide for Your Home - 3
Relish the World: Notable Caf\u00e9s You Really want to Attempt - 4
Flu cases are rising with a strain that makes older people sicker - 5
2025 Yachting Editors' Choice Awards: Yachts
5 Destinations Where Airfare Is Dropping The Most For Spring 2026, Per Dollar Flight Club Analysis
Astronomers discover never-before-seen celestial object: "Cloud 9"
Dave Coulier reveals he has tongue cancer, his 2nd diagnosis in a year, after beating non-Hodgkin lymphoma
Yemen's Houthis ready to join Iran war if needed, raising new shipping risk
Vote In favor of Your Favored Kind Of Attire
Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
Why ordering takeout or calling the dog walker might lead to a happier relationship
'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
Spain breaks jobs record with 22 million Social Security contributors











